Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effects of Evolocumab on postprandial lipid metabolism in type 2 diabetes
2016-001176-30Phase 4Completed
- Sponsor
- HYKS Institute
- Start
- Apr 2016
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, single-arm trial of evolocumab in type 2 diabetes mellitus (T2DM), sponsored by HYKS Institute. Primary endpoint: ApoB48 production rate. Started Apr 2016; status: completed.
02
Drugs
evolocumab
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2016-001176-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-001176-30.